Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NNC0113-6856 in Healthy Participants
NCT06069895Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing NNC0113-6856 with Placebo (2 arms). Primary endpoint: Number of adverse events. Started Oct 2023; status: completed.
02
Drugs
NNC0113-6856
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06069895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069895.